Neoplastic Process
BioNTech-Regeneron vs. Moderna-Merck.Cancer Vaccine and PD-1 Inhibitor Combinations.
, BioNTech, Regeneron, Moderna, Merck, Cancer Vaccine, PD-1 Inhibitor, mRNA Technology, Melanoma, Immunotherapy, Clinical Trials,
BioNTech and Regeneron Achieve Positive Phase II Results for mRNA Cancer Vaccine Combo in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, melanoma, Phase II trial, Libtayo, cemiplimab, BNT111, immunotherapy
Merck & Co.’s Keytruda Achieves $7 Billion in Quarterly Sales, Surpassing Expectations
Merck & Co., Keytruda, quarterly sales, Winrevair, pharmaceuticals, oncology
Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials
Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer
BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111
BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology
AstraZeneca’s Calquence Achieves Significant Progression-Free Survival in Phase III CLL Trial, Eyes Fixed-Duration Approval
AstraZeneca, Calquence, Phase III CLL Trial, Fixed-Duration Approval, Chronic Lymphocytic Leukemia, Progression-Free Survival
BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo
Boehringer Ingelheim Acquires Nerio Therapeutics for $1.3 Billion, Expanding Immuno-Oncology Portfolio
Boehringer Ingelheim, Nerio Therapeutics, Immuno-Oncology, Cancer Treatment, Acquisition, Small Molecule Inhibitors
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection
AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform